Profound Medical Corp. PROF
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.63M | 8.41M | 6.37M | 4.18M | 3.14M |
| Total Other Revenue | 10.45M | 10.40M | 9.73M | 10.12M | 8.70M |
| Total Revenue | 19.09M | 18.81M | 16.10M | 14.30M | 11.84M |
| Cost of Revenue | 5.39M | 5.44M | 4.71M | 3.93M | 3.62M |
| Gross Profit | 13.70M | 13.37M | 11.39M | 10.36M | 8.22M |
| SG&A Expenses | 28.46M | 30.43M | 32.05M | 31.62M | 30.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.46M | 56.92M | 57.35M | 56.53M | 54.16M |
| Operating Income | -35.37M | -38.11M | -41.25M | -42.23M | -42.32M |
| Income Before Tax | -32.52M | -38.66M | -42.32M | -39.36M | -40.69M |
| Income Tax Expenses | 227.00K | 236.00K | 252.00K | -12.00K | 44.00K |
| Earnings from Continuing Operations | -32.75 | -38.90 | -42.57 | -39.34 | -40.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.75M | -38.90M | -42.57M | -39.34M | -40.73M |
| EBIT | -35.37M | -38.11M | -41.25M | -42.23M | -42.32M |
| EBITDA | -34.88M | -37.61M | -40.69M | -41.54M | -41.56M |
| EPS Basic | -0.99 | -1.25 | -1.41 | -1.34 | -1.45 |
| Normalized Basic EPS | -0.61 | -0.78 | -0.88 | -0.84 | -0.91 |
| EPS Diluted | -0.99 | -1.25 | -1.41 | -1.34 | -1.45 |
| Normalized Diluted EPS | -0.61 | -0.78 | -0.88 | -0.84 | -0.91 |
| Average Basic Shares Outstanding | 133.48M | 127.18M | 120.93M | 115.97M | 110.40M |
| Average Diluted Shares Outstanding | 133.48M | 127.18M | 120.93M | 115.97M | 110.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |